 TopNews New Zealand | Novartis' LCZ696 to benefit patients with heart failure Express Pharma Novartis came out with the results from the phase II Paramount study showing that the investigational compound LCZ696 is the first therapy to significantly reduce a key predictor of morbidity and mortality in patients with a condition called heart ... Novartis Comes With a New Drug as Hope for Heart Failure Treatment New Novartis Phase II data show LCZ696 may provide clinical benefits in ... |
